Can Europe's Approval And Value Reviews Work More In Concert? It's A Timesaver That Might Be A Long Time Coming
In recent years, European drug approval agencies and health technology assessment authorities had little interchange, reflecting mutual disregard at best, and mutual recrimination at worst, European Medicines Agency Senior Medical Officer Hans-Georg Eichler observed.
You may also be interested in...
All too often, pharmaceutical companies and investors put up hurdles, but they can and must identify indications and assets with high future market access potential in early stages by adjusting the early screening and evaluation process.
Andrew Witty shines a positive light on value-based pricing and adds his voice to calls for harmonized HTAs across Europe.
The scandal surrounding the withdrawal of Servier’s diabetes drug Mediator (benfluorex) continues to rock the French medical establishment, but it also has drawn attention to the issue of regulators' transparency more broadly – including at the European Medicines Agency.